Mylan Says Cephalon's Patent Win Could Make Generics Scarce

Law360, New York (November 2, 2012, 5:50 PM EDT) -- Mylan Pharmaceuticals Inc. has asked the U.S. Supreme Court to review a Federal Circuit decision upholding Cephalon Inc.'s patents for the muscle relaxant Amrix, saying it is a “flawed expansion” of patent rights that could disrupt the availability of generic medications.

The Federal Circuit in April reversed a trial judge who said the patents were invalid for being obvious. Cephalon had sued Mylan in 2009 to block the release of Mylan's generic version of Amrix, a drug that delivers an extended dosage of cyclobenzaprine hydrochloride....
To view the full article, register now.